Overview

Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).

Status:
Completed

Trial end date:
2021-06-21

Target enrollment:

Participant gender:

Summary

The main objective of this study is to evaluate the efficacy of human C1 inhibitor, administered alone or in combination with icatibant (a specific bradykinin B2 receptor antagonist) on the pulmonary manifestations of COVID-19 infections.

Phase:

Phase 2

Details

Lead Sponsor:

GCS Ramsay Santé pour l'Enseignement et la Recherche

Treatments:

Icatibant